Mark Kessel is Head of the Healthcare Group and Of Counsel in the Capital Markets practice.
His practice focuses on corporate and securities, including public and private securities offerings, structured financings and mergers and acquisitions, concentrated in the biopharmaceutical industry. He is also an advisor to boards of directors and audit committees on governance and related issues, an area on which he has published extensively.
Mark also founded Symphony Capital LLC, a private equity firm investing in the clinical development programs of biopharmaceutical companies. He has served as a board member and advisor to a number of biotech boards and is currently on the board of Organovo. He is also the Chairman of the Foundation for Innovative New Diagnostics (FIND), and a strategic advisor to CinRx and other companies.
He has written for Nature Reviews Drug Discovery, The Lancet, The Scientist, Science Translational Medicine, Start-Up, BioCentury, The Wall Street Journal and Financial Times.
J.D., magna cum laude
B.A. (Honors Economics)